financetom
Business
financetom
/
Business
/
Italy's Intesa expands digital investment offer in Belgium and Luxembourg
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Italy's Intesa expands digital investment offer in Belgium and Luxembourg
Nov 7, 2025 5:56 AM

MILAN, Nov 7 (Reuters) - Italy's biggest bank Intesa

Sanpaolo said on Friday its Fideuram private banking

arm was launching a digital investment offer partnering with

BlackRock ( BLK ) in Belgium and Luxembourg.

Intesa teamed up with BlackRock ( BLK ) in 2024 to expand the

offering of Fideuram Direct, the digital wealth management

service it had launched two years earlier.

Fideuram Direct has reached 81,000 clients and 3.3 billion

euros ($3.85 billion) in assets under management, Intesa said.

Through a mobile phone app, Fideuram Direct offers

investment options such as Exchange Traded Funds (ETFs) from

BlackRock's ( BLK ) iShares, Europe's main ETF provider, it said.

Intesa plans to expand the digital service to include the

support of advisers whom clients can contact remotely.

"The initiative ... strengthens the Private Banking

Division's presence in the Belgian and Luxembourg markets, where

it already operates through Intesa Sanpaolo Wealth Management,"

the bank said.

Intesa said that in Belgium more than 80% of people access

banking services via apps at least once a month, and 26% report

increased use of digital channels compared to the previous year.

BlackRock's ( BLK ) People and Money Survey 2025 showed Belgium's

ETF market had grown by 43% since 2022, Intesa said, adding that

in Luxembourg, a financial hub, the client base was particularly

inclined towards advanced digital platforms.

($1 = 0.8575 euros)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Autolus Therapeutics Says Leukemia Drug Aucatzyl Gets EU Marketing Approval
Autolus Therapeutics Says Leukemia Drug Aucatzyl Gets EU Marketing Approval
Jul 21, 2025
07:42 AM EDT, 07/21/2025 (MT Newswires) -- Autolus Therapeutics ( AUTL ) said Monday that the European Commission has issued marketing authorization for Aucatzyl to treat patients 26 years and older with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The approval was based on the results of a clinical study published in November 2024, the company said, adding it...
Drugmaker Biogen to invest $2 billion more in North Carolina
Drugmaker Biogen to invest $2 billion more in North Carolina
Jul 21, 2025
(Reuters) -Biogen will invest an additional $2 billion in its existing manufacturing in North Carolina, the drugmaker said on Monday, as it seeks to expand its presence in the U.S. amid President Donald Trump's tariff threats. The company said the investment will go to its manufacturing plants in North Carolina's Research Triangle Park (RTP), which produce its major therapies for...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Ionis Says Donidalorsen Reduces Attack Rate in Hereditary Angioedema Patients
Ionis Says Donidalorsen Reduces Attack Rate in Hereditary Angioedema Patients
Jul 21, 2025
07:40 AM EDT, 07/21/2025 (MT Newswires) -- Ionis Pharmaceuticals ( IONS ) said Monday results from a Phase 3 study showed that its investigational therapy donidalorsen led to a 62% reduction in mean monthly attack rate among hereditary angioedema patients who switched from other prophylactic treatments. Ionis said 84% of patients surveyed preferred donidalorsen citing improved disease control, quicker administration,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved